Company Snapshot
- Ticker
- BIO
- Name
- BIO
- Sector
- None
- Currency
- 0
- Relative Volume
- None
- Market Cap
- 8480745000.000000
- Volume
- 118,034
- Avg Volume (3M)
- 216,648
BIO
BIO
Last update recent
315.00
+6.95
(+2.26%)
Market Cap
8480745000.000000
Dividend Yield
0.00%
1Y Return
None%
Beta
None
Price & Moving Averages
Interactive chart with SMA overlays and intraday breadth.
Profitability
- Revenue
- 2557475000.000000
- EPS
- -24.31
- Dividend / Share
- None
- Total Dividends
- $0.00
- Dividend Yield
- 0.0%
- Net Income
- -675900000.000000
- Net Margin
- -26.43%
- Payout Ratio
- 0.0%
- Qtly Growth YoY
- None
Valuation & Quality
- P/E
- -12.55
- Forward P/E
- None
- P/S
- 3.32
- P/B
- 1.26
- Beta
- None
- Debt / Equity
- 0.21
- Current Ratio
- 5.44
- Return on Equity
- -0.10%
- Return on Assets
- -0.07%
Technicals & Returns
- Distance vs 200 DMA
- 16.9%
- 200 DMA
- 269.47
- Distance vs 50 DMA
- 0.23%
- 50 DMA
- 314.26
- Return 1Y
- None%
- Return YTD
- None%
- Beta (Trailing)
- None
- Relative Volume
- None
Factor Lens
Plot valuation, momentum, or volume trends.
Seasonal Performance
Company Overview
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular Read more
- Name
- BIO
- Industry
- Medical - Devices
- CEO
- Mr. Norman D. Schwartz
- Employees
- 7,700
- IPO Date
- 1980-02-27
- Phone
- 510 724 7000
- Address
- None
- Website
- https://www.bio-rad.com
Dividend Yield
0.00%
TTM Distributions
$0.00
Latest News
Curated headlines from premium sources.
Federated Hermes Inc. Has $30.66 Million Position in Bio-Rad Laboratories, Inc. $BIO
Federated Hermes Inc. lowered its stake in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 9.4% in the second quarter, according to its most recent disclos…
Ariel Investments LLC Has $197.55 Million Stock Holdings in Bio-Rad Laboratories, Inc. $BIO
Ariel Investments LLC boosted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 13.0% during the second quarter, according to its most recent…
Fisher Asset Management LLC Sells 5,884 Shares of Bio-Rad Laboratories, Inc. $BIO
Fisher Asset Management LLC lowered its position in shares of Bio-Rad Laboratories, Inc. (NYSE: BIO) by 4.1% during the second quarter, according to its most r…
Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
JUPITER, Fla. and WAGENINGEN, Netherlands, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”), a global biotechnology company producing p…
Artisan Partners Limited Partnership Sells 1,670 Shares of Bio-Rad Laboratories, Inc. $BIO
Artisan Partners Limited Partnership cut its holdings in Bio-Rad Laboratories, Inc. (NYSE: BIO) by 1.4% in the undefined quarter, according to the company in i…
Digital Identity and Biometric Access Management Provider BIO-key Reports Q3 Results; Highlights Enhanced Post Quarter Balance Sheet to Support 2026 Growth Goals; Holds Investor Call 10am ET Today
Digital Identity & Biometric Access Management Provider BIO-key (Nasdaq:BKYI) Reports Q3 Results; Enhanced Post Quarter Balance Sheet Supports 2026 Growth.